Dr. Reddy's Laboratories Ltd. closed 21.94% below its 52-week high of 1,420.20 rupees, which the company achieved on August ...

Hyderabad: The Income Tax Department has issued a show cause notice to Dr Reddy's Laboratories Limited, proposing a tax ...

Dr. Reddy's Laboratories Ltd. closed 23.35% short of its 52-week high of 1,420.20 rupees, which the company reached on August ...

Sun Pharma share price has seen a 10% decline in year-to-date (YTD) performance and an 11% drop over the past six months.

With this partnership, they aim to enhance access to affordable treatments for patients suffering from autoimmune diseases ...

China's Bio-Thera Solutions has entered into an exclusive commercialization agreement with India's Dr. Reddy's Laboratories ...

Large mergers and acquisitions in the Indian pharmaceutical market are unlikely soon due to various uncertainties, says GV Prasad of Dr Reddy's Laboratories. The company is focusing on diversifying ...

HYDERABAD, India & REYKJAVIK, Iceland, March 18, 2025--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along ...

Bio-Thera Solutions and Dr. Reddy’s Laboratories SA announced that they had entered into commercialization and licensing agreements ...

Novartis AG's plan to sell its 70.68% stake in Novartis India faces challenges due to market volatility impacting valuation.

Pharma stocks plummet as Trump threatens tariffs, impacting US-dependent companies and leading to market volatility.

Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE ...